Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report |
| |
Authors: | Shankar Ananth Hall Georgina W Gorde-Grosjean Stephanie Hasenclever Dirk Leblanc Thierry Hayward Janis Lambilliotte Anne Daw Stephen Perel Yves McCarthy Keith Lejars Odile Coulomb Aurore Oberlin W Odile Wallace W Hamish Landman-Parker Judith |
| |
Affiliation: | University College Hospital NHS Trust, London, UK. ananth.shankar@nhs.net |
| |
Abstract: | PurposeTo examine whether three cycles of a low-intensity chemotherapy consisting of cyclophosphamide [500 mg/m2 – day 1], vinblastine [6 mg/m2 – days 1 and 8] and prednisolone [40 mg/m2 – days 1–7] (CVP) is safe and therapeutically effective in children and adolescents with early stage nodular lymphocyte predominant Hodgkin lymphoma [nLPHL].Patients and methodsFifty-five children and adolescents with early stage nLPHL [median age 13 years, range 4–17 years] diagnosed between June 2005 and October 2010 in the UK and France are the subjects of this report. Staging investigations included conventional cross sectional as well as 18 fluro-deoxyglucose [FDG] PET imaging. Histology was confirmed as nLPHL by an expert pathology panel.ResultsOf the 45 patients, who received CVP as first line treatment, 36 [80%, 95% Confidence Interval [CI]: (68; 92)] either achieved a complete remission [CR] or CR unconfirmed [CRu], the remaining nine patients achieved a partial response. All nine subsequently achieved CR with salvage chemotherapy [n = 7] or radiotherapy [n = 2]. Ten patients received CVP at relapse after primary treatment that consisted of surgery alone and all achieved CR. To date, only three patients have relapsed after CVP chemotherapy and all had received CVP as first line treatment at initial diagnosis. The 40-month freedom from treatment failure and overall survival for the entire cohort were 75.4% (SE ± 6%) and 100%, respectively. No significant early toxicity was observed.ConclusionsOur results show that CVP is an effective chemotherapy regimen in children and adolescents with early stage nLPHL that is well tolerated with minimal acute toxicity. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|